KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Capital Expenditures: 2014-2024

Historic Capital Expenditures for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to $492.7 million.

  • BeOne Medicines' Capital Expenditures fell 64.02% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.8 million, marking a year-over-year decrease of 56.78%. This contributed to the annual value of $492.7 million for FY2024, which is 12.32% down from last year.
  • Per BeOne Medicines' latest filing, its Capital Expenditures stood at $492.7 million for FY2024, which was down 12.32% from $561.9 million recorded in FY2023.
  • BeOne Medicines' Capital Expenditures' 5-year high stood at $561.9 million during FY2023, with a 5-year trough of $117.5 million in FY2020.
  • For the 3-year period, BeOne Medicines' Capital Expenditures averaged around $460.0 million, with its median value being $492.7 million (2024).
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 123.77% in 2021, then fell by 12.32% in 2024.
  • Over the past 5 years, BeOne Medicines' Capital Expenditures (Yearly) stood at $117.5 million in 2020, then surged by 123.77% to $262.9 million in 2021, then grew by 23.77% to $325.4 million in 2022, then spiked by 72.66% to $561.9 million in 2023, then decreased by 12.32% to $492.7 million in 2024.